[Dilip Davda] RRL is engaged in the manufacturing and marketing of pharma formulations with focused R & D and has a niche play in US market with over 95% contribution in its total revenue. The company has posted growth in its top and bottom lines for the reported periods. While it marked loss for FY23, it reported rising net profits in the following years. It has increased portfolio of specialized products for US markets. Based on its recent financial data, the issue appears aggressively priced. Well-informed investors may park funds for medium to long term. Read detail review...

Rubicon Research IPO Peer Comparison

Rubicon Research Ltd. peer comparison with similar listed entities. (As on March 31, 2025)

Company Name	EPS (Basic)	EPS (Diluted)	NAV (per share) (Rs)	P/E (x)	RoNW (%)	P/BV Ratio	Financial statements
Rubicon Research	8.82	8.68	35.53		29.02		Consolidated
Sun Pharmaceutical Industries	45.60	45.60	300.99	34.98	16.16	5.31	Consolidated
Aurobindo Pharma	59.81	59.81	560.22	18.12	11.15	1.93	Consolidated
Zydus Lifesciences	44.97	44.97	238.05	21.83	21.34	4.12	Consolidated
Strides Pharma Science	45.05	45.05	277.34	18.27	17.21	2.97	Consolidated
Dr. Reddy’s Laboratories	67.89	67.79	402.78	18.05	18.53	3.04	Consolidated
Alembic Pharmaceuticals	29.68	29.68	264.09	30.43	11.63	3.41	Consolidated
Lupin	71.95	71.69	377.18	26.64	21.00	5.07	Consolidated

Notes:

All the financial information for listed industry peers mentioned above is on an audited consolidated basis and sourced from the audited financial statements of the relevant companies for Fiscal 2025, as available on the websites of the Stock Exchanges.
Details for our Company have been sourced/ calculated from the Restated Financial Information.
Basic and diluted EPS refers to the Basic and diluted EPS sourced from the publicly available financial results of the listed industry peers for Fiscal 2025.
P/E Ratio for the listed industry peers has been computed based on the closing market price September 30, 2025 of equity shares on BSE, divided by the Diluted EPS.
Return on Net Worth is calculated as net profit or loss for the year/ period attributable to equity shareholders divided by average equity at the end of the year/ period.
Net worth means the aggregate value of the paid-up equity share capital and other equity.
Net Asset Value per share is calculated as net worth at the end of the year/ period / Weighted number of equity shares outstanding at the end of the year/ period.

Rubicon Research IPO Review by Members

Rubicon Research IPO Reviews, analysis and views by popular members. Read Rubicon Research Ltd. IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Rubicon Research IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	0	0	0	0
%	0.00	0.00	0.00	0.00

Member	Review
No recommendation found. Be the first to post the recommendation.

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

Rubicon Research IPO Review & Recommendations

Rubicon Research IPO Review Summary from brokers and analysts

Rubicon Research IPO Capital Market Rating

Rubicon Research IPO Review by Dilip Davda Not Rated

Rubicon Research IPO Peer Comparison

Rubicon Research IPO Review by Members

Rubicon Research IPO Review Summary by Members

Read more about Rubicon Research IPO